Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancer

(MedPage Today) -- SAN DIEGO -- Treatment with raludotatug deruxtecan (R-DXd) led to an "exciting" response rate among patients with heavily pretreated, platinum-resistant advanced ovarian cancer, according to an early-phase trial. In a subgroup...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news